Better treatments and risk planning for children with T-cell acute leukemia and lymphoma
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL
The team will use genetic and protein testing of tumor and bone marrow samples from children with T-cell acute leukemia or lymphoma to find why some kids respond differently to current therapies and to guide new treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11294199 on NIH RePORTER |
What this research studies
We will compare tissue and bone marrow samples from children with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) to uncover biological reasons for different treatment responses. The project uses large-scale DNA, RNA, and protein studies plus single-cell sequencing to map tumor cells and their environment. Researchers will specifically look for features linked to better outcomes with drugs like bortezomib and with stronger steroid treatment. Findings will be used to propose targeted therapies and improve how risk is assigned for future patients.
Who could benefit from this research
Good fit: Children and adolescents diagnosed with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, especially those newly diagnosed or who can provide tumor or bone marrow samples, are the ideal candidates for contributing to this research.
Not a fit: Adults, people with other types of leukemia or lymphoma, and patients without available tumor or bone marrow samples are unlikely to be eligible or to benefit directly from this grant's work.
Why it matters
Potential benefit: If successful, this work could lead to more personalized treatments that improve survival and reduce unnecessary toxic therapies for children with T-ALL and T-LL.
How similar studies have performed: A recent Children’s Oncology Group trial showed bortezomib helped T-LL but not T-ALL, and large genomic and proteomic studies in T-ALL exist, but applying these comprehensive methods to many T-LL samples is a newer effort.
Where this research is happening
Philadelphia, United States
- Children's Hosp of Philadelphia — Philadelphia, United States (Active)
Researchers
- Principal investigator: Teachey, David T. — Children's Hosp of Philadelphia
- Study coordinator: Teachey, David T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.